REXGENERO is a late-stage regenerative medicine company developing advanced cell-based therapeutics for the treatment of critical limb ischemia (CLI), a large global market with high unmet medical need
Technology:

Leading the way in technological advances for the treatment of
Peripheral Arterial Disease, Critical Limb Ischemia and Stem Cell Therapies.

Read More

Clinical Development:

The therapies we are developing at Rexgenero are various stages in their respective development. Learn developmental phases here.

Read More

News:

Click to read more news about Rexgenero research, achievements and announcement and industry related topics.

Read More

 
Cellular Therapies have the potential to successfully treat serious vascular, neurological and other disorders. Rexgenero’s technologies engineer naturally occurring stem cells to regenerate diseased tissues.

 

In our clinical programs we are investigating the effectiveness of our therapies in diabetic and non-diabetic patients with peripheral arterial disease and associated critical limb ischemia.

Our clinical candidate therapies use three different stem cell technologies: